Home » Newsletters » BioWorld

BioWorld

Oct. 8, 2004

View Archived Issues

Senate Hearing Discusses Pros, Cons Of BioShield II

Acuity Pharmaceuticals Touts RNAi Trial As Historic First'

FDA Puts TNFerade On Hold; GenVec Stock Takes Nosedive

rAAT Phase II Study Misses In Atopic Dermatitis; ProMetic Falls

Other News To Note

Theravance Prices $98M IPO; Three Others Raise $85M Total

The first full week of October proved to be a busy one for financings in the biotechnology world. (BioWorld Today) Read More

Genentech's 3Q Earnings Top Consensus Estimates